Iodixanol/iopamidol: contrast nephropathy risk not different
- PDF / 123,188 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 56 Downloads / 202 Views
1
Iodixanol/iopamidol: contrast nephropathy risk not different Among patients receiving intravascular contrast media, contrast-induced nephropathy (CIN) remains a significant safety concern, particularly among those with significant renal impairment and diabetes. To compare the incidence of CIN following administration of osmolar and isomolar contrast media in patients with diabetes and chronic kidney disease undergoing CT, researchers conducted PREDICT,* a randomised, double-blind, multicentre study. In this study, 248 such patients were randomised to receive iopamidol 370, 769 mOsm/kg (n = 125) or iodixanol 320, 290 mOsm/kg. Overall, increases in serum creatinine occurred in 5.6% of iopamidol recipients and 4.9% of those receiving iodixanol. Commenting on these findings, lead investigator and CIN expert Dr Mathew J Kuhn (Southern Illinois University School of Medicine, US), said that "the PREDICT study shows that there is no statistically significant difference in the rate of CIN between the isoosmolar iodixanol and the low-osmolar iopamidol in patients with significant renal impairment and diabetes". * Patients with renal impairment and diabetes undergoing computed tomography Bracco Diagnostics Inc. Late-Breaking Clinical Trial Results Reveal No Statistically Significant Difference between Isovue®-370 (Iopamidol Injection), or Visipaque™ 320 (Iodixanol) Injection in the Rate of CIN in High-Risk Patients Undergoing Computed Tomography. Media Release : 1 Aug 2008. Available from: 809091576 URL: http://www.bracco.com
0114-9954/10/1215-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 16 Aug 2008 No. 1215
Data Loading...
